Windlas Biotech (NSE:WINDLAS) Short-Term Capital Lease Obligation: ₹32 Mil (As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
89 GF Score
Price ₹855.75
GF Value ₹936.27
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Short-Term Capital Lease Obligation?

Windlas Biotech NSE:WINDLAS -0.19% 89 Short-Term Capital Lease Obligation is ₹32 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹936.27 (Fairly Valued). The stock has 1 warning sign investors should review.

Windlas Biotech's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2026 was ₹32 Mil.

Windlas Biotech's quarterly Short-Term Capital Lease Obligation declined from Sep. 2025 (₹19 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹32 Mil).

Windlas Biotech's annual Short-Term Capital Lease Obligation increased from Mar. 2024 (₹15 Mil) to Mar. 2025 (₹32 Mil) but then declined from Mar. 2025 (₹32 Mil) to Mar. 2026 (₹32 Mil).

Windlas Biotech Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Windlas Biotech Short-Term Capital Lease Obligation Related Terms

Windlas Biotech Short-Term Capital Lease Obligation Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Short-Term Capital Lease Obligation Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Capital Lease Obligation
Get a 7-Day Free Trial 5.16 15.32 15.14 32.29 32.19

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.29 0.00 19.32 0.00 32.19
NSE:WINDLAS
89GF Score
Windlas Biotech Ltd NSE:WINDLAS
Short-Term Capital Lease Obligation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Short-Term Capital Lease Obligation of ₹32 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Short-Term Capital Lease Obligation of ₹32 Mil as of Mar. 2026.
Is Windlas Biotech's Short-Term Capital Lease Obligation too high?
Windlas Biotech's current Short-Term Capital Lease Obligation is ₹32 Mil. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Short-Term Capital Lease Obligation compare to ZTS?
Windlas Biotech's Short-Term Capital Lease Obligation of ₹32 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Capital Lease Obligation for a Drug Manufacturers company?
A good Short-Term Capital Lease Obligation depends on the Drug Manufacturers industry context. However, Short-Term Capital Lease Obligation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Capital Lease Obligation mean?
A high Short-Term Capital Lease Obligation can signal that a stock is expensive relative to its fundamentals. Windlas Biotech's current Short-Term Capital Lease Obligation is ₹32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.27, compared to a current price of ₹855.75 — trading 8.6% below its estimated fair value. The current Short-Term Capital Lease Obligation is ₹32 Mil. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Capital Lease Obligation calculated?
Short-Term Capital Lease Obligation is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Short-Term Capital Lease Obligation is ₹32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹855.75 is trading 8.6% below its estimated GF Value™ of ₹936.27. GuruFocus considers Windlas Biotech to be Fairly Valued.

Key valuation signals for NSE:WINDLAS:

  • Short-Term Capital Lease Obligation: ₹32 Mil
  • GF Value™: ₹936.27 vs. price of ₹855.75 (8.6% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score

Get the complete analysis for NSE:WINDLAS

Short-Term Capital Lease Obligation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹855.75
Price
₹936.27
GF Value